TG Therapeutics price target raised to $6 from $4 at Goldman Sachs

Goldman Sachs analyst Corinne Jenkins raised the firm’s price target on TG Therapeutics to $6 from $4 and reiterates a Sell rating on the shares. The approval of Briumvi came with a label largely in-line with expectations, Jenkins tells investors in a research note. The analyst raised her peak sales estimate to $660M from $570M but remains cautious on the near-term outlook for sales. The multiple sclerosis is dominated by Roche’s Ocrevus and key opinion leader checks indicate limited perceived differentiation between Briumvi and Ocrevus, Jenkins says.